secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001689375-25-000009
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Q4 net income $1.1M; FDA lifts hold on ENTR-601-44; cash $420M into Q2 2027
--------------------------------------------------------------------------------

- Q4 net income $1.1M vs loss $9.5M YoY; FY net income $65.6M vs loss $6.7M.
- Collaboration revenue $37.4M Q4, $210.8M FY; R&D expenses $33.4M Q4.
- Cash $420M as of Dec 31, 2024; runway expected into Q2 2027.
- FDA lifted clinical hold on ENTR-601-44; authorized US Phase 1b MAD study for exon 44 DMD.
- MHRA authorized UK Phase 1/2 study for ENTR-601-44; regulatory filings for ENTR-601-45 in UK/EU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/0001689375-25-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000009/trda-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer